SYMPOSIUM: Oncology Drug Discovery, Translating from Target to Patient

Paris France, June 21, 2017 - Terrass Hotel

Terras Hotel, ParisThis year our annual Oncology Drug Discovery Paris symposium focuses on the efficient translation of anticancer agents from bench to bedside.

This highly dynamic field has already seen tremendous change with the acceptance of key translational tools, such as patient-derived xenografts (PDX), and now needs further evolution to continue the advancement of immunotherapeutics.

The symposium will bring together Oncology R&D and Preclinical teams from industry, academia, and medical research to facilitate cross discipline discussions on current techniques, and how to move forward with future approaches.

Discussion Topics Include:

  • How key translational oncology tools such as PDX models can be used to predict therapeutic response

  • The evolution of immuno-oncology models, and current best practices for immunotherapeutic assessment

  • How to expedite the development of novel targeted and immuno-oncology agents

Presentations & Speakers

Laurie Heilmann

Crown Bioscience Inc.
Opening Remarks

Dr. Robert Kramer

Previously BMS & Johnson & Johnson
Cancer drug discovery in the immune oncology era, from bench to bedside

Dr. Craig Fenwick

MabQuest SA
Novel anti-PD-1 antibodies not acting through PD-1/PDL-1 blockade enhance tumour clearance

Dr. Ralph Graeser

Boehringer Ingelheim Pharma GmbH & Co. KG
Should we use mouse models for immune oncology?

Dr. Eliane Piaggio

Institut Curie
Humanised mouse models applied to cancer immunotherapy

Dr. Eric Quéméneur

Engineered oncolytic viruses as modulators of the tumour microenvironment

Dr. Laure Loumagne

Assessment of humanised mouse models for the evaluation of immuno-oncology drugs

Dr. Ludovic Bourré

Crown Bioscience Europe
Therapeutic cancer vaccine development: from preclinical to human trials

Dr. Claudine Vermot-Desroches

iDD Biotech
Highly characterised PDX cells, an optimal model for preclinical efficacy studies to improve Phase II success rate

Anderson Clark
Anderson Clark

EMD Serono
The use of patient-derived xenograft (PDX) models at Merck: employing clinically relevant study design and analysis to support clinical decision-making

Attendance is free, but seats are limited, reserve your space by submitting the registration form today!

Reserve Your Seat Now!

Reserve Your Seat

Your privacy is important to us.
We'll never share your information.